<div id="readability-page-1"><ul><li>Alnylam Stock Soars 65%: Find Out What’s Behind the Gains</li></ul><p>Alnylam Pharmaceuticals <span>NASDAQ: ALNY<span></span></span> Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance despite a slower first-quarter sequential growth rate, pointing to access, international launches and prescriber expansion as key drivers for the rest of the year.</p><p>Speaking at a Bank of America healthcare conference in Las Vegas with Tazeen Ahmad, senior biotech analyst at Bank of America, Poulton described Alnylam as a 25-year-old company built around RNA interference, or RNAi, technology. He said the company has moved from being loss-making to profitable and is now focused on investing in a broader pipeline while maintaining its leadership in TTR.  </p><ul><li>3 biotech powerhouses poised to thrive amid sector rebound</li></ul><p>“We wanna be more than just a TTR company,” Poulton said, while adding that the TTR franchise remains “incredibly important” to Alnylam.  </p><h2>AMVUTTRA Launch Remains Central to Growth Outlook</h2>  <p>Ahmad noted that Alnylam has guided to total TTR revenue of $4.4 billion to $4.7 billion, which Poulton clarified is “almost all AMVUTTRA.” Poulton said Alnylam reported $910 million in TTR revenue in the first quarter, representing more than 150% year-over-year growth, though sequential growth was lower than in the fourth quarter.  </p><ul><li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li></ul><p>Poulton said the company had previously warned investors that first-quarter growth would be below the $134 million sequential increase reported in the fourth quarter. Outside the United States, Alnylam expected TTR revenue to decline by about $25 million from the fourth quarter because of pricing changes in Germany tied to the cardiomyopathy, or CM, launch. Instead, international revenue declined by $7 million, as stronger performance in Japan’s CM launch and the polyneuropathy, or PN, business offset some of the German pricing impact.  </p><p>In the United States, TTR revenue grew by $59 million in the first quarter, down from $111 million of growth in the fourth quarter. Poulton cited insurance reauthorizations early in the year and the timing of product ordering and revenue recognition as factors. He said Alnylam’s closed distribution network includes one major distribution partner handling about 80% of volume, with weekly Monday orders, Tuesday shipments and Wednesday revenue recognition. The fourth quarter had 14 Wednesdays, compared with 12 in the first quarter.  </p><p>To reach the midpoint of guidance, Poulton said Alnylam must average roughly $150 million of sequential quarterly growth for the rest of the year. He said the company expects international markets to contribute more meaningfully as the German pricing headwind does not repeat, and he expects a step-up in U.S. growth.  </p><h2>Access and Prescriber Expansion in Focus</h2>  <p>Poulton said Alnylam has built what he described as a strong foundation for AMVUTTRA access. He said more than 90% of patients can access AMVUTTRA as a first-line treatment, and most patients have no out-of-pocket copay. He also said Alnylam has established AMVUTTRA on formularies at major health systems and created a network of about 2,000 third-party infusion clinics, putting most patients within 10 miles of a clinic.  </p><p>He said the company is now focused on increasing demand by expanding the number of physicians prescribing AMVUTTRA.  </p><p>“When you get a physician to try AMVUTTRA for the first time, it leads them to prescribing more AMVUTTRA,” Poulton said. He added that Alnylam plans to report on the expansion of its prescriber base quarterly.  </p><p>Asked about second-quarter trends, Poulton declined to give specifics but said Alnylam remains confident in the guidance it reiterated. He said second-quarter performance will be important because the company needs to show an inflection from the first quarter.  </p><h2>Competition and Combination Therapy</h2>  <p>Poulton discussed upcoming data from Ionis Pharmaceuticals and AstraZeneca’s silencer program, saying Alnylam expects the study to be successful. He noted that the study is much larger than Alnylam’s HELIOS-B trial and includes a large group of patients on background tafamidis therapy.  </p><p>If Ionis and AstraZeneca show a statistically significant result in patients receiving a silencer plus tafamidis, Poulton said Alnylam believes that would likely be viewed as a class benefit. He said AMVUTTRA already has combination data in its label from a prespecified subgroup in HELIOS-B.  </p><p>However, Poulton said payer policies currently restrict combination use in much of the commercial and Medicare Advantage markets. He said a broader increase in combination therapy is more likely when tafamidis goes generic, which he said now appears to be in the middle of 2031 based on Pfizer’s announced settlements.  </p><h2>Nucresiran Positioned as Next-Generation TTR Product</h2>  <p>Poulton highlighted nucresiran, Alnylam’s third-generation TTR product, which he said is being studied in PN and CM. He said phase 1 data showed about 95% TTR knockdown, compared with AMVUTTRA in the mid-80% range, with less variability. He also said nucresiran is designed for twice-yearly subcutaneous administration, compared with AMVUTTRA’s quarterly dosing and WAINUA’s monthly dosing.  </p><p>Poulton said nucresiran could be economically meaningful because it does not carry the same royalty burden as AMVUTTRA, which he said is close to 30% on a weighted average basis. He said Alnylam has guided to operating margins around 30% through 2030, with gross margin weighed down by AMVUTTRA royalties, and sees a path to mid-40% operating margins after 2030 if nucresiran succeeds.  </p><p>Alnylam recently increased the size of its nucresiran CM outcomes study from about 1,250 patients to 1,750 patients. Poulton said enrollment was progressing quickly, and the decision was primarily intended to manage timeline risk in an event-driven study.  </p><h2>Pipeline Readouts and Balance Sheet</h2>  <p>Poulton said Alnylam expects three notable data readouts in the second half of the year:  </p><ul>   <li>A phase 1 update from its Huntington’s disease program with Regeneron, focused on safety and knockdown.</li>   <li>A phase 2 proof-of-concept readout from its plasminogen-targeting bleeding disorder program in HHT, measuring nosebleeds.</li>   <li>Early phase 1 data from its obesity program targeting ACVR1C in adipose tissue.</li> </ul>  <p>He said HHT has an estimated U.S. prevalence of about 70,000 people and currently has no on-label treatments. Alnylam also plans an R&amp;D webinar on the bleeding disorder program in the second quarter and expects to start a phase 2 study in a second indication this year.  </p><p>On the balance sheet, Poulton said Alnylam ended the year with around $3 billion in cash and expects to begin adding cash now that it is profitable. He said the company’s priorities are supporting the TTR launch, continuing internal innovation and adding external innovation, particularly in delivery technologies as Alnylam works toward reaching 10 tissues by 2030.</p><h2>About Alnylam Pharmaceuticals <span>NASDAQ: ALNY<span></span></span></h2><p>Alnylam Pharmaceuticals, Inc <span>NASDAQ: ALNY<span></span></span> is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.  </p><p>Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.</p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?</h2><p>Before you consider Alnylam Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.</p><p>While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ALNY

LABU

<p>Alnylam Pharmaceuticals CFO Jeff Poulton expressed confidence in the company's TTR revenue guidance, despite a slower growth rate in Q1. Key drivers include access, international launches, and prescriber expansion. Alnylam aims for TTR revenue of $4.4 to $4.7 billion, primarily from AMVUTTRA, with Q1 revenue at $910 million, showing over 150% year-over-year growth. The company is focused on increasing prescriber numbers and expects improved performance in Q2. Poulton also discussed competition and the potential for combination therapies as tafamidis approaches generic status in 2031.</p>

Market Beat

Alnylam Pharma

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

iShares Biotechnology ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

iShares US Pharma

VG Health

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

Direxion Daily Biotech Top 5 Bull 2X ETF

iShares Global Healthcare

ALPS Medical Breakthrough

Bank of America

Argenx

Ionis Pharma

AstraZeneca

AstraZeneca PLC

Pfizer

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build